CDC Clinical Guidelines For Risk Reduction of

STIs/HIV (New and Improved)

Jen Robinson, MS, WHNP-BC, CNM (she/they)

Adolescent Health Clinical Consultant NM Alliance for School-Based Health Care

Thanks to Dr. Gina Fullbright DNP of NM DOH for her slides on doxy PEP!





Financial disclosure

No relevant disclosures



Learning bursts + workflow Wednesdays!



CDC CLINICAL GUIDELINES FOR RISK REDUCTION OF STIS/HIV (NEW AND IMPROVED)

3:00 pm - 3:30 pm

Join us for a NMASBHC Learning Burst! CEUs/CMEs available for those who attend live. Recordings will be available on our website 2 weeks after the live Learning Burst. Recordings available here. Objectives: Register Here



WALK IN PREGNANCY TEST: WORKFLOW TO HELP SBHC STAFF PROVIDE SERVICES WHEN CLINICIANS ARE NOT PRESENT

11:00 am - 11:30 am

Join us for a NMASBHC Workflow Wednesday! CEUs/CMEs available for those who attend live. Recordings will be available on our website 2 weeks after the live Learning Burst. Recordings available here. Objectives: Register Here



Or visit www.nmasbhc.org/our-work/events-training/

Cantwait for you to join us!

Email our Adolescent Health Clinical Consultant, Jen Robinson, Jen@nmasbhc.org to setup additional trainings for your team or to schedule a 1:1 technical assistance call.



REPRODUCTIVE & SEXUAL HEALTH TRAINING



17. 24. 2025

- X Created for all clinic staff
- X In-person full day training
- X Free CME/CE
- X Breakfast and lunch provided



Location TBD

Brought to you by NMASBHC & UNM Contraception Mentoring Program



For details and to register for this free event follow the QR code.









Learning objectives

- Identify components of gender-inclusive sexual health history taking
- 2. Review updated STI screening and risk reduction recommendations
- 3. Discuss STI treatment resources and strategies





Download me! (New app as of 2021)

STI Treatment Guide Mobile App

More Comprehensive

More Integrated

More Features

Download CDC's free app for iPhone and Android devices.







Case one: Avery

- 18 year old
- "I want to be tested for everything"
- Presents to clinic with a male partner





Taking an Inclusive Sexual History – the Ps

- Pronouns
- Parts
- Partners
- Practices (& Prevention)
- Pregnancy (& Intention)



Beyond "men, women, or both"!

- Explain why you are asking questions about sexual history.
 - "I talk to all my patients about sex to help them get the care they need.
 - Some people may feel uncomfortable, and that's ok.
 - You can always ask to skip a question or tell me if you want to stop.
 - What questions or concerns do you have about that?"

Be okav with a "no"



- 18 year old
- Nonbinary, uses they/them pronouns
- Designated male at birth
- Makes sperm
- Does not want to discuss pregnancy prevention









- Has a new cis male partner (produces sperm)
- Avery has receptive sex in their back hole – usually with condoms
- ...Any other questions for Avery...?!?!

 Avery reports giving oral sex to their partner






What Sites to Screen? #NormalizeExtragenitalTesting

All sexually exposed anatomical sites

- Urethra (for people with penises)
- Cervix
- Rectum
- Pharynx







How to Test?

Self-obtained swabs are acceptable and often preferred













How to test?

Self-obtained swabs are acceptable and often preferred



Free patient self-swabbing instructions

Free!

Pharyngeal

Rectal

Vaginal

Available in 21 languages!

Order at: https://www.uwptc.org/visual-guides



- Screened for chlamydia + gonorrhea – self swab in back hole, nurse collects pharyngeal swab
- Offered HIV and syphilis screening, Avery declined due to fear of needles
- Offered condoms and lube







- Called back into clinic
- Review results and need for treatment
- Avery says "But I don't have any symptoms and neither do my partners!"





Explain why we screen asymptomatic people!!

- Screen to prevent sequelae
- Even if NO symptoms
- Remember the 3 sites! genital and extragenital testing

CHLAMYDIA CAN LOOK LIKE THIS...








UNUSUAL DISCHARGE


OR IT CAN LOOK LIKE THIS...



ABOUT 70% OF INFECTED FEMALES AND 50% OF INFECTED MEN DON'T HAVE OBVIOUS SYMPTOMS.

Expedited partner therapy – it's a thing!







providing prescriptions or medications to the patient to take to his/her partner without the health care provider first examining the partner.

Resources are available on CDC's Expedited

Partner Therapy webpage.

NM DOH EPT

Guidelines:



State, Tribal, and Local Health
Departments

Need consultation? Contact a specialist from



Management of Sex Partners

- Testing for partners! (don't forget HIV and syphilis!)
- Expedited partner therapy (EPT)
- How to write a rx if in clinic dispensing not available

Recommended EPT Regimens

For chlamydia:

- Doxycycline 100 mg PO BID x 7 days is preferred unless the partner is pregnant
- Azithromycin 1 gm PO x 1 is less effective, especially for rectal chlamydia, but can be used in partners who are pregnant or unlikely to adhere to a 7-day course of therapy

For gonorrhea:

Cefixime 800 mg PO x 1

For trichomoniasis:

- Partner(s) at risk of cervicovaginal infection: Metronidazole 500 mg PO BID x 7 days
- Partner(s) at risk of penile infection:
 Metronidazole 2 gm orally x 1






NM Landscape





Congenital Syphilis rates in infants<1 year, per 100,000 live births, New Mexico and US, and Primary and Secondary Syphilis rates in women aged 15 - 44, per 100,000 population New Mexico, 2000 - 2024



PUBLIC HEALTH ORDER NEW MEXICO DEPARTMENT OF HEALTH SECRETARY PATRICK M. ALLEN OCTOBER 17, 2024



IT IS THEREFORE ORDERED THAT:

- 1. All medical practitioners shall ensure the following testing upon consent of the patient:
- a. Adults aged 18 to 50 should be screened at least once in the next 12 months, or more often as recommended based on individual risk or pregnancy status
 - b. Syphilis testing for all pregnant people in their first trimester (or initial prenatal visit)
 - c. Syphilis testing for all pregnant people in their 3rd trimester (between 28-32 weeks gestational age)
 - d. Syphilis testing for all pregnant people at delivery
 - e. Syphilis testing for all pregnant people who present to an urgent care center or an emergency room if the patient has not received prior prenatal care
 - f. Syphilis testing of people with an intrauterine fetal demise at any gestational age
 - g. Syphilis testing for all pregnant people at correctional facilities, including prisons, jails, and juvenile detention centers, at the intervals and events ordered herein.
- THIS ORDER supersedes any previous order, proclamation, or directives to the extent they are in conflict. This Public Order shall take effect immediately and remain in effect until such time as it automatically expires one year from the date of issuance, or until such time as the NMDOH Cabinet Secretary rescinds it.





Avery (they/them) – starts doxy in clinic, given rest of rx to take home




- Current partner comes in to clinic for EPT
- Ex has EPT rx sent to pharmacy
- Recommend HIV and syphilis screening (again)



Counseling and Education – Dot phrases are your friends

- Resuming sexual activity
- Partner notification
- Follow-up testing
- Complications of chlamydial infection
- STI prevention and screening











 "Is there anything else I can do to reduce the risk of getting a STI in the future?"



Pre-exposure prophylaxis – reduce HIV risk



How effective is PrEP?

PrEP is highly effective for preventing HIV.

- PrEP reduces the risk of getting HIV from sex by about 99% when taken as prescribed.
- Although there is less information about how effective PrEP is among people who inject drugs, we do know that PrEP reduces the risk of getting HIV by at least 74% when taken as prescribed.
- PrEP is much less effective when it is not taken as prescribed.

LEARN ABOUT YOUR HIV RISK AND HOW TO LOWER IT



How long do I have to take PrEP before it is highly effective?

- PrEP reaches maximum protection from HIV for receptive anal sex (bottoming) at about 7 days of daily use.
- For receptive vaginal sex and injection drug use, PrEP reaches maximum protection at about 21 days of daily use.
- No data are available for insertive anal sex (topping) or insertive vaginal sex.

Learn more about the PrEP effectiveness estimate.





https://www.cdc.gov/hiv/clinicians/prevention/prep.html



Is PrEP right for me?

PrEP may be right for you if you test negative for HIV, and any of the following apply to you:

> **HIV RISK AND HOW** TO LOWER IT



You have had anal or vaginal sex in the past 6 months and you

- · have a sexual partner with HIV (especially if the partner has an unknown or detectable viral load).
- · have not consistently used a condom, or
- · have been diagnosed with an STD in the past 6 months.

You inject drugs and you

- · have an injection partner with HIV, or
- share needles, syringes, or other equipment to inject drugs (for example, cookers).



You have been prescribed PEP (post-exposure prophylaxis) and you

- · report continued risk behavior, or
- have used multiple courses of PEP.



If you are a woman and have a partner with HIV and are considering getting pregnant, talk to your doctor about PrEP if you're not already taking it. PrEP may be an option to help protect you and your baby from getting HIV while you try to get pregnant, during pregnancy, or while breastfeeding.

Can adolescents take PrEP?


Yes. PrEP is approved for use by adolescents without HIV who weigh at least 75 pounds (35 kg) and who are at risk for getting HIV from sex or injection drug use.





CDC STI Updates 2021







''|| 송 □

Assessment for HIV PrEP

9:16

This tool is designed to help clinicians assess indications for HIV PrEP in sexually active persons and/or in persons who inject drugs.

Assessment Tool

Medications for HIV PrEP

This tool is designed to help clinicians determine if medications for HIV PrEP are appropriate.

Medications Tool

Laboratory Tests for HIV PrEP

This tool provides clinicians with information about recommended laboratory tests for persons starting or taking HIV PrEP.

Laboratory Test Tool

Need consultation? Contact a specialist from


The Clinical Consultation Network





Doxy-PEP= Doxycycline Post Exposure Prophylaxis

- Early studies show
 - reduced risk of <u>syphilis</u> and <u>chlamydia</u> by 80% or more
 - reduced risk of gonorrhea by 50%.
- Strategy of taking the antibiotic doxycycline
 - after condomless oral or anal sex
 - to prevent chlamydia, gonorrhea, or syphilis.





https://www.ashasexualhealth.org/doxy-pep-is-a-new-strategy-to-help-prevent-stis/

Hot off the Press!!

- Kaiser Permanente Northern California
- 2253 HIV Prep users
 - 2228 Male
- >18 years of age
- Nearly 50% had an STI in the year prior to starting doxy-PEP
 - 681 chlamydia
 - 664 gonorrhea
 - 120 syphilis





Research

JAMA Internal Medicine | Original Investigation

Doxycycline Postexposure Prophylaxis and Bacterial Sexually Transmitted Infections Among Individuals Using HIV Preexposure Prophylaxis

Michael W. Traeger, PhD, MSc; Wendy A. Leyden, MPH; Jonathan E. Volk, MD; Michael J. Silverberg, PhD; Michael A. Horberg, MD; Teaniese L. Davis, PhD; Kenneth H. Mayer, MD; Douglas S. Krakower, MD; Jessica G. Young, PhD; Samuel M. Jenness, PhD; Julia L. Marcus, PhD

IMPORTANCE Doxycycline postexposure prophylaxis (doxyPEP) has been shown to decrease the incidence of bacterial sexually transmitted infections (STIs) among people assigned male sex at birth in clinical trials, but data from clinical practice are limited.

OBJECTIVE To describe early uptake of doxyPEP and evaluate changes in STI incidence following doxyPEP initiation.

DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study of adults (aged ≥ 18 years) dispensed HIV preexposure prophylaxis (FFEP) at Kaiser Permanente Northern California during November 1, 2022, to December 31, 2023, examined electronic health record data to compare HIV PFEP users dispensed and not dispensed doxyFEP and rates of bacterial STis before and after starting doxyFEP. Individuals were followed up from their first recorded STI test on or after November 1, 2020, until December 31, 2023, or discontinuation of health plan membership.

EXPOSURE Pharmacy dispensing data were used to define doxyPEP recipients

MAIN OUTCOMES AND MEASURES Demographic and clinical characteristics were compared between individuals dispensed and not dispensed doxyPEP. Primary outcomes were incident chlamydia, gonorrhea, or infectious syphilis measured as quarterly STI positivity (proportion of individuals testing positive at least once per quarter). Among doxyPEP recipients, rate ratios (RRs) compared mean quarterly STI positivity from 24 months before to 12 months after starting doxyPEP. In an exploratory analysis, STI trends were evaluated for the full cohort. stratfled by receipt of doxyPEP.

RESULTS Among 11 551 HIV PrEP users (mean [SD] age, 39.9 [12.1] years: 95.1% male), 2253 (19.5%) were dispensed doxyPEP, of whom 2228 (98.9%) were male and 1096 (48.6%) had an STI in the year before starting doxyPEP. Compared with individuals not dispensed doxyPEP, doxyPEP recipients were older (mean [SD] age, 40.4 [10.8] vs 39.8 [12.4] years; P = .04) and had used HIV PrEP longer (mean [SD], 4.2 [2.8] vs 3.4 [2.6] years; P < .001), and a higher proportion were commercially insured (2091 [92.8%] vs 8270 [88.9%]; P < .001). Among doxyPEP recipients, quarterly chlamydia positivity decreased from 9.6% (95% CI, 9.0%-10.3%) before starting doxyPEP to 2.0% (95% CI, 1.5%-2.6%) after starting doxyPEP (RR, 0.21; 95% CI, 0.16-0.27; P < .001), with significant declines for each anatomic site of Infection. Quarterly gonorrhea positivity decreased from 10.2% (95% CI, 9.6%-10.9%) before starting doxyPEP to 9.0% (95% CI, 8.0%-10.1%) after starting doxyPEP (RR, 0.88; 95% CI, 0.77-1.00: P = .048): site-specific declines were significant for rectal (RR, 0.81: 95% CL 0.67-0.97: P = .02) and urethral (RR, 0.56: 95% CI, 0.40-0.79: P = .001) gonorrhea, but not pharyngeal gonorrhea. Quarterly syphilis positivity decreased from 1.7% (95% CI, 1.4%-1.9%) before starting doxyPEP to 0.3% (95% CI, 0.2%-0.6%) after starting doxyPEP (RR, 0.20; 95% CI, 0.11-0.37; P < .001). Positivity for STIs remained stable in Individuals not dispensed

CONCLUSIONS AND RELEVANCE This study found that receipt of doxyPEP was associated with substantial declines in chlamydia and syphilis incidence and modest declines in urethral and rectal gonorrhea incidence among individuals using HIV PTEP. These findings suggest that doxyPEP may offer substantial benefits for reducing population-level STI transmission with broader implementation.

JAMA Intern Med. doi:10.1001/jamainternmed.2024.7186 Published online January 6, 2025. ■ Invited Commentary

Related article

Supplemental content

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Michael W. Traeger, PhD, MSc, Department of Population Medicine, Harvard Pilgrim Health Care Institute, 401 Park Dr, Ste 401 E, Boston, MA 02215 (michael, traeger@hphcl.harvard. edu).

Doxy-PEP decreases bacterial STI rates





Summary of Doxy-PEP Efficacy


Doxy-PEP WORKS!

- Especially for chlamydia and syphilis (less so for GC)
- Well studied in MSM and TGW
- Data is limited or lacking for other groups
 - Lack of efficacy in AFAB seems likely to adherence
 - New studies underway
- No protection for the "H's"
 - HPV, HSV, HIV, Hepatitis, and Mpox



Providing Doxy-PEP










Counseling & Instructions: Doxy-PEP

- Timing
 - Ideally within 24 hours no later than 72
 - No more than one 200 mg dose in 24 hours
- Interactions
 - Dairy/calcium
- Possible side effects
 - GI-nausea, vomiting, pain
 - Sun sensitivity
 - Esophagitis





Follow-up

- Screen for STIs every 3 months
 - All potentially exposed sites
- Treat any STI according to STI Treatment Guidelines (cdc.gov)
- Ongoing counseling
- Consider periodic lab work: LFTs, renal function, CBC







Lingering Questions: Doxy-PEP

Antibiotic Resistance

- GC, Staph aureus, MRSA
- Could induce resistance
- Unclear what the clinical implications would be (Doxy not used to treat GC)
- Doxycycline remains 100% effective for T. pallidum & C. trachomatis.


Effects on Gut Microbiome

- Good bacteria vs. bad bacteria
- "Doxy-PEP use over 6 months did not significantly alter bacterial microbiome diversity of total bacterial abundance" (Chu et al-Poster CROI 2024)



Lingering Questions Summary: Doxy-PEP

- While there are lingering questions about antimicrobial resistance & the gut microbiome...
- Those concerns do not necessarily outweigh the potential benefits of doxy-PEP given STI epidemics





NM DOH Health Advisory Notice: Doxy-PEP



MICHELLE LUJAN GRISHAM Governor

PATRICK M. ALLEN Cabinet Secretary

NEW MEXICO HEALTH ALERT NETWORK (HAN)

Doxycycline Post-Exposure Prophylaxis (doxy-PEP) for the Prevention of

Bacterial Sexually Transmitted Infections August 23, 2023

Recommendations for clinicians

Prescribing Doxy-PEP

Evidence

Safety





Take home points



- #NormalizeExtragenitalTesting
- Routinely offer syphilis and HIV screening
- Use CDC STI app + resources
- Reach out to Jen with questions and/or to discuss implementation issues!

jarobinson@salud.unm.edu



UNM Contraception Mentoring Program Webinar Series

One hour free CME/CEU per session!





Abnormal Uterine Bleeding & Contraceptive Management

Online event

Wednesday, February 26, 2025 at 4:00 PM MST





Emergency Contraception

Online event

Wednesday, March 26, 2025 at 4:00 PM MDT





Premenstrual Disorders and Contraceptive Management

Online event

Wednesday, April 30, 2025 at 4:00 PM MDT





Perimenopause and Contraception

Online event

Wednesday, May 28, 2025 at 4:00 PM MDT







NM DOH Nurse Helpline: 1-833-SWNURSE

Navigate patients to care

Help providers connect with next steps re:

- STI guidelines
- Reproductive health
- Vaccines
- + more!





NM DOH STI Online Resource Guide







Learning bursts + workflow Wednesdays!



CDC CLINICAL GUIDELINES FOR RISK REDUCTION OF STIS/HIV (NEW AND IMPROVED)

3:00 pm - 3:30 pm

Join us for a NMASBHC Learning Burst! CEUs/CMEs available for those who attend live. Recordings will be available on our website 2 weeks after the live Learning Burst. Recordings available here. Objectives: Register Here



WALK IN PREGNANCY TEST: WORKFLOW TO HELP SBHC STAFF PROVIDE SERVICES WHEN CLINICIANS ARE NOT PRESENT

11:00 am - 11:30 am

Join us for a NMASBHC Workflow Wednesday! CEUs/CMEs available for those who attend live. Recordings will be available on our website 2 weeks after the live Learning Burst. Recordings available here. Objectives: Register Here



Or visit www.nmasbhc.org/our-work/events-training/

Cantwait for you to join us!

Email our Adolescent Health Clinical Consultant, Jen Robinson, Jen@nmasbhc.org to setup additional trainings for your team or to schedule a 1:1 technical assistance call.



REPRODUCTIVE & SEXUAL HEALTH TRAINING



ReDate 07. 24. 2025

- X Created for all clinic staff
- X In-person full day training
- X Free CME/CE
- X Breakfast and lunch provided



Location TBD

Brought to you by NMASBHC & UNM Contraception Mentoring Program




For details and to register for this free event follow the QR code.













Jen Robinson MS, WHNP-BC, CNM, RN jen@nmasbhc.org

Sign in code! Thanks for being here!





